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| CD8 + MEMORY T CELL G ENER ATI ON
Several studies have suggested that T cells are programmed to become memory during the early stages of the priming phase. 9 In vaccinated humans, memory CD8 + T cells arise from a rapidly dividing effector pool formed in the first 14 days post challenge, subsequent to re-engagement of naive like chromatin landscapes. 10 Similarly, in the lymphocytic choriomeningitis virus (LCMV) model, long-lived memory CD8 + T cells emerge from de-differentiation of fate-permissive Teff cells. 11 These findings concur with single cell RNAseq (scRNAseq) analysis of early CD8 + T cell specification during adoptive transfer in the LCMV model, in which Teff and memory differentiation emerge from an early burst of transcriptional activity
followed by epigenetic refinement. 12 Work in the Listeria monocytogenes and LCMV models have previously classified subsets of Teff cells based upon their ability to give rise to memory CD8 + T cells.
These precursor subsets are defined by differential expression of the IL-7 receptor (CD127) and the killer cell lectin-like receptor G1 (KLRG1). Memory precursor effector cells (MPEC; CD127 hi KLRG1 neg )
are characterized by BCL2 expression, a longer lifespan and proliferative potential in response to homeostatic cytokines (IL-7/IL- 15) or antigenic re-challenge, while short-lived effector cells (SLEC; CD127 lo KLRG1 hi ) have a shorter lifespan and reduced homeostatic proliferative capacity. [13] [14] [15] The recent finding that effector differentiation precedes memory formation is complicit with this 'separate precursor' model, and the long-held knowledge that memory potential is non-equivalent among Teff cells, since certain effectors may preferentially re-engage naïve like programs that specify memory fate. Although not necessarily contradictory, it is also noteworthy that production of memory CD8 + T cells has also been reported to occur in the absence of an overt effector response. 16 Data from several infection models have shown that SLEC differentiation is favored by increased signal 1 (prolonged antigen exposure, TCR affinity/avidity/peptide concentration, low intraclonal competition) and signal 3 (eg, high levels of, IFNγ, IL-12, while brief TCR stimulation, truncated infection periods (eg, via administration of antibiotics), defects in inflammatory cytokine signaling, enhanced anti-inflammatory cytokine availability (eg, TGFb, IL-10) or the presence of regulatory T cells promotes MPEC development or derivation of less differentiated memory subsets. 15 Costimulation via CD28-CD80/CD86 is also required during priming to prevent anergy and tolerance, while ligation of TNF super family receptors (TNFSRs) on CD8 + T cells (CD27, OX40, 41BB, CD30) promotes proliferation and survival and enhances the quality of the recall response. [17] [18] [19] [20] Similarly, ligation of HVEM receptor on CD8 + T cells by BTLA (on CD8α DC) is required for Teff cell survival and development of protective immune memory in response to bacterial and viral infection, in part via promoting MPEC persistence. 21 Another key factor in the generation of memory CD8 + T cells is CD4 + T cell help. CD8 + T cells primed in the absence of CD4 + T cells have impaired long-term survival and display defective ability to respond against secondary challenge. 22 The mechanisms behind the requirement of CD4 + T cells
are not completely understood, however, the interaction between
CD40 on CD8 + T cells with CD40L on CD4 + T cells and the secretion of IL-15 from these cells have shown to be relevant in the generation
Teff cells with enhanced ability to become memory. 23, 24 More recently, CTLA-4 on CD4 + T regulatory (Treg) cells has been shown to force memory T cell quiescence, suggesting that helper and regulatory CD4 + T cell subsets may be required, for optimal memory CD8 + T cell generation and homeostasis, respectively. 25 , and CD95. 26 Tcm and Tem cells were originally described in mouse and human based on the expression of CD44, CCR7 and CD62L, and CD45RO and CCR7, respectively. 27 Relative two differentiation programs that share an overlapping molecular basis which manifests in hyporesponsiveness to self-peptide. 94 The deletion of autoreactive T cell clones during central tolerance is incomplete. Therefore, peripheral self-tolerance is a necessary evolutionary strategy that prevents auto-immunity via inhibition of effector responses to cognate antigen following sub-optimal costimulation (ie, in the absence of DAMP/PAMP signalling on APC).
| CIRCUL ATING MEMORY CD8 + T CELL SUBS E TS
Context and system-dependent differences (including cytokine environment and TCR avidity) may bring about variable degrees of hyporesponsiveness, altering the requirement for antigen persistence, as well as the magnitude or co-occurrence of defects seen in cytokine production/proliferation, in some instances leading to T cell deletion. [94] [95] [96] [97] [98] [99] Self-tolerance may also result from induction of subsets to PD-L1 blockade in LCMV chronic infection. 115, 121 Similar to what has been proposed in tolerance, chronic infection appears to impose epigenetic re-programming associated with T cell exhaustion. 122, 123 In this module transcription factors, cytokine and TCR signaling loci appear in closed chromatin conformations at later stages of infection coincident with increased accessibility of the PD-1 locus. 124, 125 It has been suggested that this epigenetically fixed state of CD8 + T cell dysfunction is accountable for lack of checkpoint blockade activity. 126 In agreement with this, 
| THE IN CEP TI ON AND INHIB ITI ON OF ANTI -TUMOR IMMUNIT Y
The unprecedented survival rates achieved with checkpoint blockade have fueled renewed optimism in cancer immunotherapy.
However, only a minority of patients are sensitive to treatment and few experience durable clinical benefit. 138 Results from these models suggest that tumor-specific CD8 + T cell dysfunction represents a unique program of differentiation, distinguishable from acute/chronic infection, or tolerance that is caused by chronic neoantigen exposure in the TME. How this molecular program of dysfunction is altered in models testing neoepitopes derived from mutated self-proteins (that may have a broad range of affinities)
remains to be seen. Work from Schietinger's group has subsequently
shown that the irreversible dysfunction in this model is linked with epigenetic reprogramming and a fixed chromatin state. 151 In this re- 
| MEMORY T CELL SUBS E TS IN TUMOR IMMUNIT Y: S TUD IE S IN CLINI C AL SAMPLE S
TILs isolated from colon, renal, lung, ovarian, bladder, and melanoma tumors have been phenotyped using various combinations of markers to define activation status (eg, HLA-DR, CD38, Ki67), cytotoxicity (PRF, GZMb), transcription factor profile (EOMES, Tbet), tissue residency (CD69, CD103) and linear differentiation (CD45RA, CCR7, CD27, CD28). 166, 167 The majority of tumor infiltrating CD8 + T cells exhibit dysfunction-associated phenotypes, including broad and intense TCIR expression (eg, PD-1, LAG-3, TIM-3 and TIGIT). 105 For example, in clear cell renal cell carcinoma TILs exhibited increased markers of residency (CD69), activation (CD38) and TCIR (ICOS, LAG-3, PD-1, TIM-3) relative to T cells in normal tissue. 167 In non-small cell lung cancer (NSCLC) the fre- 178 The study of MAIT cells in tumors remains in its infancy, but has been recently reviewed elsewhere. 179 Clearly, much work is required to reconcile these potential with better clinical outcome, 184 and that TIL retaining a 'young'
(CD27 + CD28 + expression, longer telomeres) phenotype can mediate regression in melanoma. 185 On aggregate, these data indicate that less differentiated, circulating memory CD8 + T cell subsets of humans and mice exhibit favorable anti-tumor activity in vivo.
Remarkably, it has also been shown that peripheral activation of effectors may also be integral for the success of immunotherapy. 
| TISSUE RE S IDENT MEMORY CD8 + T CELL S IN ANTI -TUMOR IMMUNIT Y
The role of Trm cells in tumor protection is yet to be fully discerned. 
| OUTS TANDING QUE S TIONS
The current body of T cell profiling data from solid cancer specimens or chronicity/level/dosage of exposure (eg, ubiquitous truncal neoantigens vs sub clonal neoantigens) remains to be seen. 147, 150, 192 In this regard it is interesting that the burden of clonal neoantigens and high affinity frameshift insertion and deletion encoded neoantigens associate with response to checkpoint blockade, yet how the pool of cells fostered by these favorable genomic landscapes differs from low mutational burden patients is largely unknown. 147, 193 
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